Please assess the completion status of the following clinical trial:

Trial Title: Laquinimod Phase IIa Study in Active Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects diagnosed with Crohn's disease for at least 3 months prior to screening.~2. Moderate to severe Crohn's disease patients as determined by the CDAI score~Exclusion Criteria:~1. Subjects who have had recent bowel surgery~2. Subjects with clinically significant GI obstructive symptoms~3. Subjects with a clinically significant or unstable medical or surgical condition~4. Subjects with unstable doses of standard of care medications (5-ASA, antibiotics, oral corticosteroids, immunosuppressants )~5. Women who are pregnant or nursing or who intend to be during the study period.~6. Women of child-bearing potential who do not practice an acceptable method of birth control

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Laquinimod (Type: EXPERIMENTAL): Laquinimod 0.5mg/day, 1mg/day, 1.5mg/day, 2mg/day (sequential cohorts)
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).